Perfil clínico e epidemiológico de pacientes com câncer pancreático de um centro oncológico privado brasileiro
Nenhuma Miniatura disponível
Data
2023-11
Tipo de documento
Artigo Científico
Título da Revista
ISSN da Revista
Título de Volume
Área do conhecimento
Ciências da Saúde
Modalidade de acesso
Acesso embargado
Editora
Autores
CONTE, Giovanna Dissenha
GONÇALVES, Mariá de Oliveira
Orientador
MENEGOTTO, Vicente Martorano
Coorientador
ANDRADE, Leonardo de Brittes
Resumo
Introdução: O câncer de pâncreas é altamente mortal e representa um desafio à saúde pública. Este estudo investigou pacientes com câncer de pâncreas tratados em um centro privado de referência em Santa Catarina para entender seu perfil sociodemográfico e clínico, visando melhorar diagnóstico precoce e estratégias de prevenção. Metodologia: Foram analisados 78 prontuários de pacientes diagnosticados e tratados para câncer pancreático entre janeiro de 2017 e junho de 2022. Resultados: Observou-se o perfil homem, acima de 71 anos (46,2%), branco, com companheiro, procedentes da Grande Florianópolis, não fumante (62,8%), não etilista (80,8%), IMC com peso ideal (47,4%), emagrecido (70,5%), apresentando dor abdominal (80,9%), não diabético (48,7%), com marcador CA 19-9 elevado (73,1%), TNM IV (50%), tumor localizado na cabeça pancreática, tipo histológico adenocarcinoma, Tomografia computadorizada foi o exame mais realizado, seguido da Ressonância Magnética, diagnóstico histopatológico disponível pela peça cirúrgica, tratamento preconizado de primeira linha com Folfirinox (74,4%). O tempo de sobrevida a partir do diagnóstico foi maior que 24 meses (38,5%), com óbito no momento do corte temporal (62,8%). Conclusão: A alta incidência e mortalidade tornam imprescindíveis o fortalecimento e ampliação das medidas de combate ao câncer pancreático, tendo em vista os fatores de risco bem estabelecidos, como tabagismo, etilismo, obesidade e diabetes. Mais estudos devem ser conduzidos para incrementar o screening e diagnóstico precoce, sendo esse a chave para a diminuição da carga e impacto da doença.
Introduction: Pancreatic cancer is highly lethal and poses a challenge to public health. This study investigates patients with pancreatic cancer treated at a private referral center in Santa Catarina to understand their sociodemographic and clinical profiles, with the aim of improving early diagnosis and prevention strategies. Methods: We analyzed 78 medical records of patients diagnosed and treated for pancreatic cancer between January 2017 and June 2022. Results: The observed profile was predominantly male, over 71 years of age (46.2%), white, with a partner, from the Greater Florianópolis area, non-smokers (82.8%), non-alcoholic (80.8%), with a BMI within the ideal range (47.7%), experiencing weight loss (70.5%), abdominal pain (80.9%), non-diabetic (48.7%), with an elevated Ca 19-9 marker (73.1%), TNM stage IV (50%), a tumor localized in the pancreatic head, of the histological type Adenocarcinoma. Computed Tomography was the most frequently performed exam, followed by Magnetic Resonance Imaging. The diagnosis was often achieved through surgical resection, and the primary treatment endorsed was Folfirinox (74.4%). Conclusion: The survival time from diagnosis exceeded 24 months in 38.5% of cases, with 62.8% deceased at the time of this analysis. The high incidence and mortality rates underscore the need to strengthen and expand efforts to combat pancreatic cancer, taking into account well-established risk factors such as smoking, alcohol consumption, obesity, and diabetes. Further studies are necessary to improve screening and early diagnosis, which is essential for reducing the burden and impact of this disease.
Introduction: Pancreatic cancer is highly lethal and poses a challenge to public health. This study investigates patients with pancreatic cancer treated at a private referral center in Santa Catarina to understand their sociodemographic and clinical profiles, with the aim of improving early diagnosis and prevention strategies. Methods: We analyzed 78 medical records of patients diagnosed and treated for pancreatic cancer between January 2017 and June 2022. Results: The observed profile was predominantly male, over 71 years of age (46.2%), white, with a partner, from the Greater Florianópolis area, non-smokers (82.8%), non-alcoholic (80.8%), with a BMI within the ideal range (47.7%), experiencing weight loss (70.5%), abdominal pain (80.9%), non-diabetic (48.7%), with an elevated Ca 19-9 marker (73.1%), TNM stage IV (50%), a tumor localized in the pancreatic head, of the histological type Adenocarcinoma. Computed Tomography was the most frequently performed exam, followed by Magnetic Resonance Imaging. The diagnosis was often achieved through surgical resection, and the primary treatment endorsed was Folfirinox (74.4%). Conclusion: The survival time from diagnosis exceeded 24 months in 38.5% of cases, with 62.8% deceased at the time of this analysis. The high incidence and mortality rates underscore the need to strengthen and expand efforts to combat pancreatic cancer, taking into account well-established risk factors such as smoking, alcohol consumption, obesity, and diabetes. Further studies are necessary to improve screening and early diagnosis, which is essential for reducing the burden and impact of this disease.
Palavras-chave
Câncer pancreático, Oncologia, Perfil de saúde, Tratamento oncológico, Sobrevida